New Delhi, India – 110 016
South Delhi Pharma, New Delhi, India
Under Named Patient Supply, SDP serve you through the quality pharmaceutical products as per your needs. Established in the year 1996. SDP have earned global reputation in the market and has widest range of Anti Cancer medicines in India. To get the best price/cost of medicines in India, Call at 9891296838 or Email query@southdelhipharma.com to discuss.
ROZLYTREK is a prescription medicine for non-small cell lung cancer (NSCLC) treatment.
INDICATIONS AND USAGE
ROZLYTREK is a kinase inhibitor indicated for the treatment of:
• Adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumors are ROS1-positive. (1.1)
• Adult and pediatric patients 12 years of age and older with solid tumors
This indication is approved under accelerated approval based on tumor response rate and durability of response. Continued approval for this indication may be contingent upon verification and description of clinical benefit in the confirmatory trials.
DOSAGE FORMS & STRENGTHS
Capsules: 100 mg and 200 mg
Manufactured By: Genentech
Prescribing Information URL: Click Here
South Delhi Pharma can facilitate the supply of “ROZLYTREK (entrectinib) capsules” to all locations in India and other part of countries after fulfilling the legal requirement (if applicable). All Anticancer drugs available upon request. To get best price please share your mobile number to receive quotes from South Delhi Pharma.
Disclaimer: Trademark shown are property of their respective owners and South Delhi Pharma (SDP) India does not lay any claim on them.
Get in touch with us at South Delhi Pharma (SDP), and one of our team will be on hand to help with any queries you may have.
The SDP is open
Monday to Friday.
Business hours: 09:30 A.M to 18:30 P.M.
Contact Number:
M:+91-9891296838 / P:+91-11- 26532129
Email ID:
info@southdelhipharma.com
Entrectinib, sold under the brand name Rozlytrek, is an anti-cancer medication used to treat ROS1-positive non-small cell lung cancer and NTRK fusion-positive solid tumors. It is a selective tyrosine kinase inhibitor (TKI), of the tropomyosin receptor kinases (TRK) A, B and C, C-ros oncogene 1 (ROS1) and anaplastic lymphoma kinase (ALK).
It was approved for medical use in the United States in August 2019, in Australia in May 2020, and in the European Union in July 2020.
